CR20230294A - Método para preparar pralsetinib - Google Patents

Método para preparar pralsetinib

Info

Publication number
CR20230294A
CR20230294A CR20230294A CR20230294A CR20230294A CR 20230294 A CR20230294 A CR 20230294A CR 20230294 A CR20230294 A CR 20230294A CR 20230294 A CR20230294 A CR 20230294A CR 20230294 A CR20230294 A CR 20230294A
Authority
CR
Costa Rica
Prior art keywords
pralsetinib
preparing
compounds
processes
compositions useful
Prior art date
Application number
CR20230294A
Other languages
English (en)
Inventor
Vincent Poral
Joshua Waetzig
Albert Cornelis Dros
Gordon D Wilkie
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of CR20230294A publication Critical patent/CR20230294A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/04—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers
    • C07C257/06—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers having carbon atoms of imino-carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms, or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/16—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se proporcionan, en parte, compuestos y composiciones útiles para preparar pralsetinib. En la presente también se proporcionan procesos para preparar pralsetinib.
CR20230294A 2020-12-04 2021-12-03 Método para preparar pralsetinib CR20230294A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063121330P 2020-12-04 2020-12-04
PCT/US2021/061754 WO2022120136A1 (en) 2020-12-04 2021-12-03 Method of preparing pralsetinib

Publications (1)

Publication Number Publication Date
CR20230294A true CR20230294A (es) 2023-07-26

Family

ID=79170866

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230294A CR20230294A (es) 2020-12-04 2021-12-03 Método para preparar pralsetinib

Country Status (13)

Country Link
US (1) US20240059672A1 (es)
EP (1) EP4255892A1 (es)
JP (1) JP2024501429A (es)
KR (1) KR20230113612A (es)
CN (1) CN116724024A (es)
AR (1) AR124245A1 (es)
AU (1) AU2021390534A1 (es)
CA (1) CA3203970A1 (es)
CR (1) CR20230294A (es)
IL (1) IL303286A (es)
MX (1) MX2023006512A (es)
TW (1) TW202237567A (es)
WO (1) WO2022120136A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210096A1 (es) 2018-04-03 2021-01-12 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
EP4219454B1 (en) * 2022-01-28 2025-11-19 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Highly efficient process for the preparation of 4-fluoro-1h-pyrazole or salts thereof
IT202300006819A1 (it) 2023-04-06 2024-10-06 Olon Spa Processo per preparare pralsetinib in forma amorfa, e relativi intermedi in forma cristallina.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007756A1 (ja) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
IN2013MU00848A (es) 2013-03-19 2015-05-01 Glenmark Generics Ltd
CN104844567B (zh) 2015-04-23 2017-03-29 暨南大学 一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法
SI3371171T1 (sl) * 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
CN107980784B (zh) 2017-12-13 2020-05-26 中国农业大学 5-氨基吡唑类化合物在调节植物生长方面的应用
CN108341782A (zh) 2018-03-30 2018-07-31 南京哈柏医药科技有限公司 3-氨基-5-甲基吡唑的合成工艺
CN111440151A (zh) * 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
CN111362923A (zh) * 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法

Also Published As

Publication number Publication date
MX2023006512A (es) 2023-10-24
CN116724024A (zh) 2023-09-08
KR20230113612A (ko) 2023-07-31
AR124245A1 (es) 2023-03-01
WO2022120136A1 (en) 2022-06-09
AU2021390534A1 (en) 2023-06-22
CA3203970A1 (en) 2022-06-09
TW202237567A (zh) 2022-10-01
JP2024501429A (ja) 2024-01-12
IL303286A (en) 2023-07-01
US20240059672A1 (en) 2024-02-22
EP4255892A1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
MX2023006512A (es) Método para preparar pralsetinib.
MX2025004604A (es) Nuevos compuestos triheterociclicos
TN2023000250A1 (en) Inhibiting ubiquitin-specific protease 1 (usp1)
MX2021003819A (es) Moduladores de alfa-1 antitripsina.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12021553018A1 (en) New egfr inhibitors
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
ZA202309516B (en) Anti-ccr8 antibodies
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
MX2022001641A (es) Composiciones fermentadas y procedimientos de preparacion de las mismas.
PH12022552177A1 (en) Heteroaryl heterocyclic compounds and uses thereof
AU2018282018A1 (en) Compositions and methods for reducing flatulence
MX2021006808A (es) Novedosa psicosa-6-fosfato fosfatasa, composicion para la produccion de psicosa que comprende la misma y procedimiento para la produccion de psicosa mediante el uso de la misma.
ZA202211168B (en) Fragrance composition
CR20250103A (es) Moduladores de la alfa-1 antitripsina
MX2025003568A (es) Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap)
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
MX2022012302A (es) Formas polimórficas de metopimazina novedosas.
MX2025004326A (es) Metodo para preparar maribavir
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
MX2025007548A (es) Pirroloquinazolinonas espirociclicas sustituidas y piperidinoquinazolinonas espirociclicas sustituidas
MX2023002288A (es) Inhibidores de la secrecion de proteinas.
ZA202408113B (en) Improved process for the manufacture of osimertinib
WO2022212827A3 (en) Methods and compositions for treating clostridiodes difficile infections